Drugs / KDT501
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02444910 | Apr → Nov 2015 | type 2 diabetes mellitus | KinDex Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KDT501 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02444910 ↗ |
| Action | Activate | “Nonclinical studies demonstrate agonist activity of KDT501 at the G-protein coupled receptor 120” NCT02444910 ↗ |
| Route | Oral | “KDT501 is an orally administered product designed” NCT02444910 ↗ |